{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:01:12Z","timestamp":1783620072670,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shire Development LLC"},{"name":"Shire International GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40263-017-0443-y","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T07:43:28Z","timestamp":1498808608000},"page":"625-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe"],"prefix":"10.1007","volume":"31","author":[{"given":"David R.","family":"Coghill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Hern\u00e1ndez","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Soutullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"issue":"8","key":"443_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.euroneuro.2010.11.007","volume":"21","author":"D Coghill","year":"2011","unstructured":"Coghill D. Pragmatic measures in paediatric psychopharmacology\u2014are we getting it right? Eur Neuropsychopharmacol. 2011;21(8):571\u201383.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"443_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/S003329170500471X","volume":"36","author":"SV Faraone","year":"2006","unstructured":"Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159\u201365.","journal-title":"Psychol Med"},{"issue":"1","key":"443_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopsych.2008.10.005","volume":"65","author":"C Lara","year":"2009","unstructured":"Lara C, Fayyad J, de Graaf R, Kessler RC, Aguilar-Gaxiola S, Angermeyer M, et al. Childhood predictors of adult attention-deficit\/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46\u201354.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"443_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942\u20138.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"443_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ije\/dyt261","volume":"43","author":"GV Polanczyk","year":"2014","unstructured":"Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434\u201342.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"443_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1037\/0021-843X.111.2.279","volume":"111","author":"RA Barkley","year":"2002","unstructured":"Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit\/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279\u201389.","journal-title":"J Abnorm Psychol"},{"issue":"6","key":"443_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/0269881111412095","volume":"26","author":"M Seixas","year":"2012","unstructured":"Seixas M, Weiss M, Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012;26(6):753\u201365.","journal-title":"J Psychopharmacol"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/NDT.S9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"443_CR9","first-page":"2275","volume":"10","author":"J Sharman","year":"2014","unstructured":"Sharman J, Pennick M. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis Treat. 2014;10:2275\u201380.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","volume":"36","author":"JC Ermer","year":"2016","unstructured":"Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341\u201356.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"443_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364\u201373.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"443_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2007.04.015","volume":"62","author":"J Biederman","year":"2007","unstructured":"Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970\u20136.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"443_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450\u201363.","journal-title":"Clin Ther"},{"issue":"10","key":"443_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","volume":"23","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208\u201318.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"443_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"443_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L, Study G. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"6","key":"443_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40263-014-0166-2","volume":"28","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497\u2013511.","journal-title":"CNS Drugs"},{"issue":"7","key":"443_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1017\/S1092852900016898","volume":"13","author":"RL Findling","year":"2008","unstructured":"Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. CNS Spectr. 2008;13(7):614\u201320.","journal-title":"CNS Spectr"},{"issue":"10","key":"443_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1017\/S1092852900024056","volume":"14","author":"R Weisler","year":"2009","unstructured":"Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. CNS Spectr. 2009;14(10):573\u201385.","journal-title":"CNS Spectr"},{"issue":"1","key":"443_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/cap.2011.0088","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(1):11\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"443_CR21","unstructured":"National Institute for Health and Clinical Excellence (NICE). The NICE guideline on diagnosis and management of ADHD in children, young people and adults. Londong: NICE; 2013. http:\/\/www.nice.org.uk\/guidance\/cg72. Accessed 17 Sept 2015."},{"issue":"12","key":"443_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40263-013-0104-8","volume":"27","author":"RW Dittmann","year":"2013","unstructured":"Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit\/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27(12):1081\u201392.","journal-title":"CNS Drugs"},{"issue":"6","key":"443_CR23","doi-asserted-by":"publisher","first-page":"647 e1","DOI":"10.1016\/j.jaac.2014.01.017","volume":"53","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647 e1\u2013657 e1.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"443_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/cap.2008.0165","volume":"19","author":"RL Findling","year":"2009","unstructured":"Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit\/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19(6):649\u201362.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"443_CR25","first-page":"1","volume":"246","author":"RJ Kuczmarski","year":"2002","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002;246:1\u2013190.","journal-title":"Vital Health Stat 11"},{"issue":"1","key":"443_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/104454601750143500","volume":"11","author":"CW Hughes","year":"2001","unstructured":"Hughes CW, Rintelmann J, Emslie GJ, Lopez M, MacCabe N. A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adolesc Psychopharmacol. 2001;11(1):77\u201393.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"443_CR27","unstructured":"Posner K. Suicidality issues in clinical trials: Columbia suicidal adverse event identification in FDA safety analyses. 2007. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-01-CU-Posner.ppt. Accessed March 24."},{"issue":"12","key":"443_CR28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.biopsych.2010.08.019","volume":"69","author":"SR Chamberlain","year":"2011","unstructured":"Chamberlain SR, Robbins TW, Winder-Rhodes S, Muller U, Sahakian BJ, Blackwell AD, et al. Translational approaches to frontostriatal dysfunction in attention-deficit\/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. 2011;69(12):1192\u2013203.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"443_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF02088471","volume":"9","author":"NM Morris","year":"1980","unstructured":"Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980;9(3):271\u201380.","journal-title":"J Youth Adolesc"},{"key":"443_CR30","volume-title":"ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation. New York: Guilford Press; 1998."},{"issue":"338","key":"443_CR31","first-page":"218","volume":"76","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impression scale. ECDEU Assess Man Psychopharmacol-Revis Vol DHEW Publ No ADM. 1976;76(338):218\u201322.","journal-title":"ECDEU Assess Man Psychopharmacol-Revis Vol DHEW Publ No ADM"},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-244X-10-67","volume":"10","author":"SJ Kooij","year":"2010","unstructured":"Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.","journal-title":"BMC Psychiatry"},{"key":"443_CR33","unstructured":"Elvanse 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg and 70\u00a0mg capsules, hard [prescribing information]. Hampshire: Shire Pharmaceuticals Limited; 2016. https:\/\/www.medicines.org.uk\/emc\/medicine\/27442\/SPC\/Elvanse+30mg,+50mg+%26+70mg+Capsules,+hard\/. Accessed 12 Nov."},{"issue":"7","key":"443_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4088\/JCP.12m08144","volume":"74","author":"LA Adler","year":"2013","unstructured":"Adler LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, et al. Lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(7):694\u2013702.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"443_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/01.chi.0000157550.94702.a2","volume":"44","author":"JJ McGough","year":"2005","unstructured":"McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):530\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"443_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/01.chi.0000173291.28688.e7","volume":"44","author":"T Wilens","year":"2005","unstructured":"Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015\u201323.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"443_CR37","first-page":"24","volume":"49","author":"SV Faraone","year":"2010","unstructured":"Faraone SV, Spencer TJ, Kollins SH, Glatt SJ. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2010;49(1):24\u201332.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"443_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3\u00a0years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"443_CR39","first-page":"894","volume":"48","author":"S Cortese","year":"2009","unstructured":"Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit\/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry. 2009;48(9):894\u2013908.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"443_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1087054708314844","volume":"12","author":"SV Faraone","year":"2009","unstructured":"Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009;12(4):308\u201315.","journal-title":"J Atten Disord."},{"issue":"6","key":"443_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1087054710371195","volume":"15","author":"JM Giblin","year":"2011","unstructured":"Giblin JM, Strobel AL. Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. J Atten Disord. 2011;15(6):491\u20138.","journal-title":"J Atten Disord"},{"issue":"2","key":"443_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/YIC.0b013e3283364411","volume":"25","author":"HW Kim","year":"2010","unstructured":"Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit\/hyperactivity disorder. Int Clin Psychopharmacol. 2010;25(2):107\u201315.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"443_CR43","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1542\/peds.2015-1708","volume":"136","author":"KM Kidwell","year":"2015","unstructured":"Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015;136(6):1144\u201353.","journal-title":"Pediatrics"},{"key":"443_CR44","unstructured":"Vyvanse [prescribing information]. Lexington, MA: Shire LLC; 2017. http:\/\/pi.shirecontent.com\/pi\/pdfs\/vyvanse_usa_eng.pdf. Accessed Nov 12."},{"issue":"1","key":"443_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-012-0019-9","volume":"27","author":"J Martinez-Raga","year":"2013","unstructured":"Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15\u201330.","journal-title":"CNS Drugs"},{"issue":"1","key":"443_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2261-12-41","volume":"12","author":"AN Westover","year":"2012","unstructured":"Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord. 2012;12(1):41.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"443_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11920-013-0379-y","volume":"15","author":"AG Winterstein","year":"2013","unstructured":"Winterstein AG. Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies. Curr Psychiatry Rep. 2013;15(8):379.","journal-title":"Curr Psychiatry Rep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-017-0443-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:47:47Z","timestamp":1628617667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-017-0443-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0443-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"assertion":[{"value":"30 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was funded by Shire Development LLC. Writing and editing assistance for this paper was funded by Shire International GmbH. Shire International GmbH also funded open access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BC and BY are employees of Shire and own stock or stock options. The following authors have received compensation for serving as consultants or speakers for, or they or the institutions they work for have received research support or royalties from, the companies or organizations indicated: TB (Actelion, Hexal Pharma, Lilly, Medice, Novartis, Otsuka, Shire, and Vifor Pharma); DRC (Eli Lilly, Janssen-Cilag, Medice, Novartis, Oxford University Press, Shire, and Vifor Pharma); PN (Lilly, Otsuka, and Shire); IHO (Alicia Koplowitz Foundation, Eli Lilly, Forest, Janssen-Cilag, Junta de Andaluc\u00eda, Roche, Shire, Shire Pharmaceuticals Iberica S.L., and Sunovion); CAS (Alicia Koplowitz Foundation, Editorial M\u00e9dica Panamericana, Eli Lilly, EUNSA [University of Navarra Press], Fundaci\u00f3n Caja Navarra, Janssen, Mayo Eds, Medice\/Juste, NeuroTech Solutions, Rubi\u00f2, Shire, Sociedad Vasco-Navarra de Psiquiatr\u00eda, University of Navarra Research Projects [PIUNA], and Wolters Kluwer); AZ (Angelini, EduPharma, Lilly, Lundbeck, Otsuka, Oxford University Press, Roche, Shire, Takeda and Vifor Pharma).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient\u2019s parent\/legal guardian provided written, informed consent, and assent was obtained from each participant (as applicable) before they took part in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}